Advicenne ordinary shareholders’ meeting convened on December 20, 2019, for this purpose  

Nîmes, France, November 15, 2019 (6:00 p.m. CET) – Advicenne (Euronext: ADVIC – FR0013296746), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare kidney disease, today announced its intention to appoint Dr David Horn Solomon as Chairman of its Board of Directors. Such an appointment is subject to his prior appointment as a member of the Board of Directors by the ordinary shareholders’ meeting convened for that purpose on
December 20, 2019. Dr Luc-André Granier will remain Chief Executive Officer as well as a member of the Board of Directors of the company.